Cartesian Therapeutics (RNAC)Director bought ~$206K

~$206K

Approx. value · 30K sh @ $6.86

54K

Holds after · shares reported

Traded

Dec 4, 2025

Filed

Dec 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 2, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 2, 2025, the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) appointed June Seymour as the Company’s Chief Accounting Officer, effective upon the commencement of Ms. Seymour’s full-time employment with the Company on October 27, 2025 (the “Effective Date”).”
2. Oct 15, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 15, 2025, Cartesian Therapeutics, Inc. (the “Company”) eliminated the position of Chief Scientific Officer and delivered a notice of termination of employment without cause to Christopher Jewell, Ph.D., who currently serves as the Company’s Chief Scientific Officer, each effective as of November 14, 2025.”
3. Oct 29, 2025Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“In connection with her recent appointment as Executive Chair of another publicly-traded company and the additional responsibilities and time commitment related thereto, on October 29, 2025, Carrie S. Cox, a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board, effective immediately.”
4. Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
5. Dec 4, 2025 · this disclosureInsider · 12 days before an 8-KDirector purchased ~$206K of RNAC shares in the open market

What came next

1. Dec 16, 2025Company filing · Form 8-K · Executive change, Amendments to the Registrant's Code of EthicsChanged a top executive or board member, and changed or waived its code of ethics (and 1 more item)“On December 16, 2025, the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) appointed Adrian Bot, M.D., Ph.D. as a Class II director.”
2. Jan 6, 2026Insider · 3 peopleInsiders: 3 sales (~$259K)
3. Mar 9, 2026Company filing · Form 8-K · ResultsReported its results
4. Mar 26, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cartesian Therapeutics

OQRO holds no insider, Congress, fund or contract record for Cartesian Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RNAC page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cartesian Therapeutics

• SEC Form 4Jan 8, 2026
• SEC Form 4Jan 8, 2026
• SEC Form 4Jan 8, 2026
• SEC Form 13F-HRMay 23, 2025
• SEC Form 4Apr 11, 2025
• SEC Form 4Apr 11, 2025

Everything OQRO holds on this company is on its RNAC page.